Per-Johan Jakobsson
cofounder
Gesynta Pharma
Gesynta Pharma develops pharmaceuticals that inhibit the pro-inflammatory enzyme mPGES-1 to reduce inflammation and pain associated with chronic conditions like endometriosis. Their lead candidate, Vipoglanstat, is currently in phase II clinical trials, demonstrating significant reductions in endometrial lesions and pain-related symptoms.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$57.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Chronic inflammatory conditions like endometriosis cause significant pain and affect millions of women. Current treatments often have limited efficacy or undesirable side effects, highlighting the need for novel therapeutic approaches.
Solution
Gesynta Pharma is developing pharmaceuticals that target the pro-inflammatory enzyme mPGES-1 to reduce inflammation and pain. Their lead drug candidate, Vipoglanstat (GS-248), is a non-hormonal, potentially disease-modifying treatment for endometriosis. Vipoglanstat has demonstrated a favorable safety profile and beneficial pharmacological properties in Phase I and II clinical trials. Preclinical studies show that Vipoglanstat significantly reduces endometrial lesions and positively impacts pain-related parameters. Gesynta Pharma's second drug candidate, GS-073, has the same mechanism of action as Vipoglanstat and is ready to enter Phase I clinical trials for chronic inflammatory pain.
Target Audience
The primary target audience includes women suffering from endometriosis and individuals with chronic inflammatory pain conditions.
Features
- Vipoglanstat (GS-248): A selective mPGES-1 inhibitor in Phase II clinical trials for endometriosis.
- GS-073: A second mPGES-1 inhibitor ready to enter Phase I clinical trials for chronic inflammatory pain.
- Non-hormonal mechanism of action, potentially avoiding side effects associated with hormonal therapies.
- Disease-modifying potential, targeting the underlying inflammatory process in endometriosis.